|
|
|
|
|
20.05.26 - 08:03
|
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update (Business Wire)
|
|
|
Consolidated net sales of TWYMEEG® in Japan for the first quarter of 2026 reached JPY 2.3 billion (€12.8 million 1), up 36% compared to the first quarter of 2025.
Poxel generated revenue of €1.277 million for the first quarter of 2026.
Consolidated net sales of TWYMEEG® in Japan for Sumitomo Pharma2 reached JPY 9.35 billion (€51 million), up 40% compared to the previous fiscal year.
During Sumitomo Pharma's fiscal year 20253, Poxel received royalties of 10% on TWYMEEG® net sales
Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG® sales for its fiscal year 20264.
Sumitomo Pharma notably expects TWYMEEG® net sales to exceed the JPY 10 billion threshold.
Upon reaching this threshold, Poxel will receive a contractual milestone payment of JPY 1 billion (€5.5 million1), with the royalty rate increasing from 10% to 12%.
LYON, France--(BUSINESS WIRE)--Regulatory News:
Poxel (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovat...
|
|
|
|
|
|
|
13.05.26 - 08:01
|
Japan OKs 1st iPS Regenerative Medicine for Insurance Coverage (Nippon)
|
|
|
Tokyo, May 13 (Jiji Press)--A Japanese health ministry council on Wednesday approved the public health insurance coverage for a regenerative medicine for Parkinson's disease produced from induced pluripotent stem, or iPS, cells, effective from May 20. With the approval by the Central Social Insurance Medical Council, which advises the health minister, Amchepry from Japan's Sumitomo Pharma C......
|
|
|
02.04.26 - 11:00
|
Sumitomo Pharma (4506.JP) Slides 9.6% on the Day as Tariff Risks Escalate (AAStocks)
|
|
|
Sumitomo Pharma (4506.JP) closed at JPY2,018.5 today (2nd), down 9.57% for the day. UK media reported that the administration of US President Donald Trump is preparing to impose a 100% tariff on certain pharmaceutical products, with the new measures aimed at forcing drugmakers to accelerate expansion of domestic production in th......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.11.25 - 18:51
|
Poxel Reports Revenue for the Third Quarter 2025 (Business Wire)
|
|
|
TWYMEEG® sales continue to grow in Japan, up 5% in the last quarter (July-September) compared to the previous quarter and up 40% compared to the third quarter of 2024
Gross TWYMEEG® for Sumitomo Pharma amounted to JPY 5 billion for the first half ended September 30, supporting its full-year forecast of JPY 11.2 billion for the fiscal year ending March 31, 20261, which would represent a 47% increase compared to fiscal year 2024 sales
LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reports its revenue for the quarter ended September 30, 2025, and for the first nine months of the fiscal year.
Nicolas Trouche, Chief Executive Officer of Poxel, states: “Dear shareholders, as you know, Poxel is in a very difficult situation due t...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
